Tagged with DIA

Ireland Deirdre Bourke, Country Lead at Eli Lilly’s Irish affiliate, highlights the strategic importance of Ireland to Lilly’s global operations, their exciting upcoming pipeline, the challenges and opportunities she foresees for Lilly in Ireland, and her own professional transition from managing Lilly’s diabetes portfolio to Lilly’s overall commercial activities in Ireland.…

Philippines Kuntal Baveja, country head and president of Sandoz Philippines Corporation discusses the company’s expanding portfolio in the country and how the booming generic industry over the past years has helped to expand access to affordable medications to the Filipinos, still pointing out that there is much room for expansion in…

Singapore Paul Bruhn, Regional Business Head Asia, Oceania, MEA of Nestlé Health Science in Singapore, elaborates on the intricacies of these diverse regions and the strategic importance of Singapore as a hub for the region. You manage the AOA region out of Singapore, could you elaborate on what this region encompasses…

Singapore The founder and CEO of Vela Diagnostics, Michael Tillmann underscores the motivating drivers behind the establishment of the company and how their unique portfolio of automated PCR and NGS solutions have made clinical laboratory life easier for all companies across the molecular diagnostics value chain. He further highlights the crucial…

Switzerland Michael Cobas Meyer of Eli Lilly Switzerland reveals how these are very exciting times for the company, particularly given an extremely rich pipeline in the areas of diabetes, oncology and bio-medicines; how the challenge will be to transition from their existing portfolio to new products; and why Lilly´s focus is…

Mexico Dr. David Kershenobich Stalnikowitz, General Director of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán on the myriad issues surrounding diabetes in Mexico and how the Mexican healthcare system can evolve. You have highlighted the importance of the institute operating as a reference center. What have been some…

Pharma A native of Serbia, Aleksandar Ciric provides his first impressions of the Slovak market and business atmosphere, emphasizing the transparency and market accessibility. His current priority at Novo Nordisk is to develop the local organization by developing its people in order to maintain a competitive edge. After eight months in Slovakia,…

Healthcare In light of the recently released OECD Reviews of Health Systems: Mexico 2016, Roberto Martinez, general director of the OECD Mexico Center for Latin America, reveals the OECD’s key findings and strategic priorities for fostering inclusive growth and better health outcomes in Mexico, while the Center keeps on strengthening its…

Health Tackling both obesity and diabetes is a primary objective of the National Academy of Medicine of Mexico and requires a holistic, multidisciplinary approach, according to Dr. Graue Wiechers, president of the National Academy of Medicine and rector at UNAM (National Autonomous University of Mexico), the largest university in Latin America.…

Health In the year of Gen Suisse’s 25th anniversary, CEO Daniela Suter talks supporting dialogue between scientists and politicians on life sciences in Switzerland, educating the general population, the attractiveness of the Swiss community for scientists, and her goals for the future. Could you give our international viewers an overview of…

Pharma The Country Head Commercial Business of Cipla Czech Republic reviews the challenges faced since Cipla began Czech operations two years ago, the company’s expertise in the respiratory segment, and how high quality products have led to rapid success. You have worked in pharma all of your life including for AstraZeneca,…

Global In part two of an exclusive interview, Novo Nordisk’s Maziar Mike Doustdar expands on the potential of emerging markets to foster innovation, managing risk, local partnerships, and the company’s unwavering commitment to fighting diabetes.   To what extent can immature markets become sources of innovation in healthcare technologies? Does limited infrastructure not…